owing to Pharmaq Analytiq hy Pharmaq; and
owing to Pharmaq Limited by Pharmaq.
"Existing Term and Revolving Facilities Agreement" means the term and revolving facilities agreement dated 11 May 2013 (as amended) and entered into between the Parent and the Issuer as borrowers and The Governor and Company of the Bank of Ireland, Danske Bank, Norwegian Branch of Danske Bank A/S and Nordea Bank Norge ASA as lenders.
"Fee Letter" means the fee letter entered or to be entered into between the Issuer and the Bond Trustee setting out the fees and expenses payable by the Issuer to the Bond Trustee in connection with the Transaction.
"Final Maturity Date" means 28 March 2019.
"Finance Charges" means, for the Relevant Period, the aggregate of interest accrued (whether in cash or capitalised) in respect of any Borrowings of any Group Company during that Relevant Period but:
(a)
excluding any amortisation of fees, costs and expenses incurred in connection with
the raising of any Borrowings; and
